These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Intra-hepato-arterial administration of cis-diammine-dichloroplatinum II (CDDP) for primary or metastatic hepatic cancer].
    Author: Maeta M, Koga S, Osaki Y, Kanayama H, Oda M, Murakami A, Hirooka Y.
    Journal: Gan No Rinsho; 1984 Jul; 30(8):899-904. PubMed ID: 6433066.
    Abstract:
    To study the effectiveness of CDDP for hepatic cancer, intra-hepato-arterial administration of CDDP (0.8-1.0 mg/kg/week) combined with 5-FU (250 mg/body/day) was performed for 10 patients with primary or metastatic hepatic cancer. As the results, partial response was obtained in 6 of 8 evaluable patients. However, the adverse effect was very high rate; leucopenia, thrombocytopenia and vomiting (nausea) were observed in 9, 6 and 6 of 10 patients respectively. The dose limiting factor of CDDP was not a nephrotoxicity but a bone marrow depression in this series. Though a noticeable antitumor effect of this modality was obtained, some improvements should be applied to it to decrease the adverse effect.
    [Abstract] [Full Text] [Related] [New Search]